Caffeine
Viewing r1 — Apr 25, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Caffeine (1,3,7-trimethylxanthine) is a naturally-occurring stimulant of the xanthine class. It is the most widely consumed psychoactive substance on Earth, with over 80% of Western adults using it daily.[1] Caffeine is a competitive antagonist at adenosine A₁ and A₂A receptors,[2] producing its effects by blocking the brain's endogenous fatigue and sleep signaling.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First isolated from coffee beans by Friedlieb Ferdinand Runge in 1819,[3] caffeine was among the earliest psychoactive compounds to be chemically identified. The 1999 review by Fredholm et al. consolidated decades of research into a unified mechanistic account,[1] while the landmark CAP trial established caffeine citrate as standard of care in neonatal medicine.[4] Unlike nearly every other psychoactive substance, caffeine occupies a position of near-total cultural normalization — its drug status rarely acknowledged by its users.
Subjective effects include wakefulness, cognitive enhancement, mood elevation, and increased motivation. The experience is primarily one of cognitive restoration — caffeine lifts fatigue-degraded performance back toward baseline rather than enhancing cognition above rested levels,[5] a distinction lost on most chronic users. Dose-dependent anxiety, restlessness, and disrupted sleep are characteristic unsought effects, with ADORA2A genetic variants creating marked individual variation in the anxiogenic threshold.[6][7]
Caffeine produces low-to-moderate physical dependence with a DSM-5-recognized withdrawal,[8] and has a wide therapeutic index — lethal doses require quantities far beyond normal beverage consumption.[9][10] The primary acute risk comes from concentrated powder and energy drink products, which have caused fatalities at doses impossible to reach through beverages alone;[11] tolerance develops through adenosine receptor adaptation,[12] though wakefulness-promoting effects remain partially preserved even with chronic use.[13] Caffeine is among the most thoroughly characterized psychoactive substances in pharmacology, with over a century of clinical and epidemiological data.
History[edit]
Discovery
Caffeine was first isolated in 1819 by the German chemist Friedlieb Ferdinand Runge, who extracted it from coffee beans provided by Johann Wolfgang von Goethe.[3] French chemists Pierre Jean Robiquet, Pierre-Joseph Pelletier, and Joseph Bienaimé Caventou independently isolated the compound in 1821. Hermann Emil Fischer achieved the first total synthesis in 1895, confirming the trimethylxanthine structure — work that contributed to his 1902 Nobel Prize in Chemistry.[3]
Clinical and scientific significance
The foundational mechanistic account of caffeine came in 1999, when Fredholm et al. published a comprehensive review establishing adenosine receptor antagonism as the primary mediator of caffeine's central effects.[1] Clinical use had preceded this understanding by decades: caffeine citrate was already standard treatment for neonatal apnea, and the 2006 Caffeine for Apnea of Prematurity (CAP) trial confirmed its efficacy and demonstrated improved neurodevelopmental outcomes.[4]
Present-day status
Caffeine is consumed worldwide in coffee, tea, cocoa, yerba maté, guarana, energy drinks, soft drinks, and over-the-counter stimulant tablets. Over 80% of adults in Western societies consume it in pharmacologically active doses daily, making it the most widely consumed psychoactive substance on Earth.[1] Unlike virtually every other compound in this encyclopedia, caffeine occupies a position of near-total cultural normalization — its psychoactive status rarely acknowledged by its users.
The name "caffeine" derives from the French caféine, coined during the independent French isolations of 1821. Historical synonyms reflect its botanical ubiquity: theine (from tea) and guaranine (from guarana) were once treated as distinct substances before chemical analysis proved them identical to caffeine.[14] Caffeine occurs naturally in over 60 plant species, where it functions as a natural insecticide — a defense mechanism that humans co-opted into the world's most popular drug.
Chemistry[edit]
Structure
Caffeine (1,3,7-trimethylxanthine) belongs to the methylxanthine family — a subclass of xanthine alkaloids within the broader purine group. The molecule is built from a fused pyrimidine-imidazole ring system with two carbonyl groups and three methyl substituents at nitrogen positions 1, 3, and 7.[14][15]
| Molecular formula | C₈H₁₀N₄O₂ |
| Molecular weight | 194.19 g/mol |
Caffeine contains no chirality centers and exists as a single achiral species.
Structural relatives
Caffeine's three closest structural relatives are its own primary metabolites, each produced by removal of one methyl group: paraxanthine (1,7-dimethylxanthine, ~84% of metabolic output), theobromine (3,7-dimethylxanthine, ~12%), and theophylline (1,3-dimethylxanthine, ~4%).[16] All three retain pharmacological activity, with paraxanthine being the most potent adenosine receptor antagonist among them.
Physical properties
Caffeine presents as a white, odorless, bitter crystalline powder with a melting point of 235–238°C.[15] It possesses both water-soluble and fat-soluble character — a dual solubility profile that underlies its near-complete absorption from the gut and ready passage across the blood–brain barrier.[16][15]
Natural occurrence
Caffeine occurs naturally in the seeds, leaves, and fruits of over 60 plant species, where it functions as a natural insecticide and allelopathic agent. Major dietary sources include Coffea species (coffee beans, ~1–2% caffeine by dry weight), Camellia sinensis (tea leaves, ~2–5%), Theobroma cacao (cocoa beans, ~0.1–0.4%), Ilex paraguariensis (yerba maté), and Paullinia cupana (guarana, up to ~6%).[14]
Pharmacology[edit]
Mechanism of action
Caffeine is a non-selective competitive antagonist at adenosine receptors, with the A₁ and A₂A subtypes carrying the greatest significance in the brain.[17][2] Adenosine is an endogenous neuromodulator that accumulates during wakefulness, progressively suppressing neuronal activity and promoting sleep. By occupying adenosine's binding sites without activating them, caffeine blocks this inhibitory signal — effectively releasing the brake on arousal, attention, and dopaminergic neurotransmission.[1]
This mechanism operates at ordinary dietary doses because peak plasma concentrations after a typical cup of coffee (100–200 mg caffeine) fall squarely within the functional antagonist range.[16] At doses exceeding 500 mg, secondary mechanisms become relevant: inhibition of phosphodiesterase enzymes (raising intracellular cAMP) and direct mobilization of calcium from intracellular stores, contributing to cardiac stimulation.[18][19]
Caffeine also elevates circulating catecholamines (epinephrine and norepinephrine) through central sympathetic activation, contributing to cardiovascular and anxiety-related effects.[10]
Downstream effects on neurotransmitters
A₂A receptor blockade in the striatum enhances dopaminergic signaling — the basis for caffeine's mild mood elevation, locomotor activation, and weak reinforcing properties.[1] A₁ receptor blockade releases glutamate transmission from tonic inhibition, influencing arousal and memory consolidation.[12]
These indirect effects distinguish caffeine from direct-acting stimulants like amphetamine, which release dopamine rather than disinhibiting existing signaling. Caffeine does not directly bind serotonin receptors but can modulate serotonergic tone indirectly through adenosine–dopamine interactions.
Pharmacokinetics
Caffeine is administered almost exclusively by mouth. Absorption from the gut is near-complete (~99–100% bioavailability), with peak blood levels reached within 30–60 minutes.[16] The half-life averages 3–5 hours in non-smoking adults but ranges from 1.5 to 9.5 hours depending on individual metabolic capacity.[16]
The liver enzyme CYP1A2 handles approximately 95% of caffeine metabolism, producing three active metabolites: paraxanthine (~84%), theobromine (~12%), and theophylline (~4%).[16][20] Because caffeine clearance depends so heavily on this single enzyme, factors that alter CYP1A2 activity produce dramatic changes in caffeine exposure:
Neuroscience[edit]
Where it acts
Caffeine's stimulant properties originate in the striatum, where A₂A receptors form physical complexes with dopamine D₂ receptors on medium spiny neurons.[2] When adenosine binds A₂A, it reduces D₂ receptor sensitivity to dopamine; caffeine blocks this interaction, enhancing dopaminergic transmission and producing mild mood elevation and locomotor activation.[1]
In the prefrontal cortex and hippocampus, A₁ receptor blockade disinhibits glutamate signaling, sharpening attention and working memory.[12] In sleep-wake circuitry, caffeine blocks the homeostatic sleep signal carried by adenosine in the basal forebrain and nucleus accumbens, sustaining wakefulness beyond its natural limit.[13]
Cognitive normalization and neuroprotection
Caffeine functions as a cognitive normalizer — it restores performance degraded by fatigue, sleep deprivation, or aging rather than enhancing cognition above a rested baseline.[5] This distinction explains the common finding that caffeine "improves" attention and reaction time primarily in tired or sleep-deprived individuals.
Epidemiological data consistently associate habitual caffeine consumption with reduced Parkinson's disease risk,[23][24] and less consistently with reduced Alzheimer's risk.[25] The proposed mechanism involves A₂A antagonism reducing neuroinflammation in the basal ganglia, but Mendelian randomization studies have not confirmed a causal relationship.[26]
- Paraxanthine's role: Caffeine's primary metabolite, paraxanthine, is a more potent adenosine antagonist with a different side-effect profile.[16] Its independent contribution to the caffeine experience remains unquantified.
- Incomplete wakefulness tolerance: tolerance develops to locomotor stimulation and cardiovascular effects but not fully to wakefulness promotion.[13] The receptor-level mechanism for this differential remains unresolved.
- ADORA2A pharmacogenomics: Genetic variation in the A₂A receptor gene influences anxiety sensitivity to caffeine,[6] but the full scope of these polymorphisms — including effects on tolerance, withdrawal severity, and neuroprotective benefit — is poorly characterized.
Subjective Effects[edit]
Caffeine's subjective profile is shaped less by set and setting than most psychoactive substances and more by habitual consumption pattern and genetic background. In caffeine-naïve users, the experience is predominantly one of clean, focused wakefulness with mild mood elevation; in chronic users, much of the perceived benefit represents restoration of a withdrawal-suppressed baseline rather than genuine enhancement.[5] ADORA2A receptor polymorphisms create marked individual variation — the same dose that produces calm focus in one person may trigger restless agitation in another.[6]
Compared to amphetamine or other dopamine-releasing stimulants, caffeine produces substantially weaker euphoria and reinforcement, with a gentler onset and shorter commitment. Its stimulant character is best described as permissive — removing adenosine's brake on existing arousal systems — rather than the imposed stimulation of direct catecholamine releasers.
Effect Grid
At common doses (100–300 mg oral, equivalent to 1–3 cups of brewed coffee), the full stimulant profile emerges. Wakefulness and alertness are pronounced. Attention and vigilance are consistently improved, with reduced reaction time and enhanced sustained focus. Thought acceleration is evident, and motivation for task completion increases. Mood is mildly elevated, with increased sociability and verbal fluency.
Physically, increased heart rate, mild blood pressure elevation, and diuresis are expected. Mild tremor may be noticeable in caffeine-naïve individuals. Appetite suppression is common. Sleep onset will be delayed if consumed within 6 hours of bedtime.
At the upper end of this range (200–300 mg), some individuals — particularly those with ADORA2A polymorphisms or anxiety disorders — may experience restlessness, irritability, or mild anxiety rather than focused alertness.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Taste suppression · Touch enhancement · Light sensitivity · Tinnitus · Auditory hallucinations · External hallucinations
Auditory hallucinations · External hallucinations
Appetite suppression · Insomnia · Respiratory stimulation · Physical fatigue · Restlessness · Headache · Heart rate perception changes · Trembling · Nausea · Dehydration sensation · Muscle tension · Pain suppression · Motor control enhancement · Dizziness · Excessive sweating · Bruxism · Diarrhea · Pupil dilation · Temperature dysregulation · Yawning · Sexual arousal enhancement · Tactile euphoria · Motor control impairment · Vomiting · Seizure threshold reduction
Physical fatigue · Restlessness · Headache · Heart rate perception changes · Trembling · Nausea · Dehydration sensation · Muscle tension · Pain suppression · Motor control enhancement · Dizziness · Excessive sweating · Bruxism · Diarrhea · Pupil dilation · Yawning · Sexual arousal enhancement · Tactile euphoria · Motor control impairment · Vomiting · Seizure threshold reduction
Motivation enhancement · Analysis enhancement · Information processing enhancement · Memory enhancement · Cognitive euphoria · Thought organization · Motivation suppression · Cognitive flexibility · Pattern recognition enhancement · Language enhancement · Cognitive dysphoria · Confusion · Thought disorganization · Thought loops
Cognitive euphoria · Thought organization · Motivation suppression · Cognitive flexibility · Pattern recognition enhancement · Language enhancement · Cognitive dysphoria · Confusion · Thought disorganization · Thought loops
Anhedonia · Dysphoria
Ego inflation
Timeline
First perceptible effects emerge 10–30 minutes after ingestion — a subtle sense of increasing alertness and reduced fatigue. Effects may appear faster on an empty stomach.
Alertness builds steadily as plasma levels rise toward Cmax. Mental clarity sharpens, motivation increases, and physical energy becomes noticeable.
Maximum stimulation coincides with peak plasma concentration (Tmax ~30–60 min). Alertness, focus, and mood elevation are at their strongest. At higher doses, anxiety and restlessness may dominate.
Sustained but gradually diminishing stimulation as plasma levels decline through the elimination half-life. Productive wakefulness continues, though peak sharpness fades.
Effects taper to baseline over 1–2 hours. Fatigue may return, sometimes more noticeably than before dosing due to adenosine rebound. Mild headache possible in regular users as levels drop.
Residual subclinical stimulation persists for 2–4 hours after subjective effects resolve, with potential for sleep disruption if consumed in the afternoon or evening.
⚠ Do not drive or operate machinery if experiencing fatigue rebound or if caffeine was used to compensate for significant sleep deprivation.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- theophylline · theobromine · paraxanthine
Toxicity
Acute toxicity
Caffeine has a wide therapeutic index relative to its active dose range. The estimated lethal dose is approximately 150–200 mg/kg — roughly 10.5–14 g for a 70 kg adult, equivalent to approximately 80–100 cups of brewed coffee.[9][10]
The overdose toxidrome progresses dose-dependently[9][10]:
- Mild-moderate (>500–1,000 mg): Palpitations, rapid heart rate, tremor, anxiety, nausea, headache
- Severe (>1,000 mg): Heart rhythm disturbances, metabolic acidosis, low potassium, seizures, muscle breakdown
- Life-threatening (>5 g): Cardiac arrest, cardiovascular collapse, respiratory failure, death
For severe caffeine overdose: activated charcoal if within 1–2 hours of ingestion; IV beta-blockers (esmolol) for heart rhythm disturbances; benzodiazepines for seizures; dialysis for extreme overdose; correct low potassium and metabolic acidosis.[9]
Cardiovascular effects
Caffeine acutely raises blood pressure and heart rate via catecholamine release. It constricts blood vessels in the brain[27] — a property exploited therapeutically in headache treatment. At high doses, particularly via energy drinks, caffeine can trigger dangerous heart rhythms through cardiac calcium overload.[28] Sudden cardiac arrest in young adults has been documented in temporal association with energy drink consumption.[11]
Concentrated caffeine products
In 2018, the FDA effectively banned direct-to-consumer sale of highly concentrated or pure powdered caffeine following multiple overdose fatalities.[29] A single teaspoon of pure caffeine powder contains approximately 3,200 mg — eight times the recommended daily maximum — making accurate dosing without laboratory equipment essentially impossible.
Pregnancy
A meta-analysis of 60 publications quantified dose-dependent risks per 100 mg daily caffeine increment[30]:
- +14% risk of miscarriage (95% CI: 10–19%)
- +19% risk of stillbirth (95% CI: 5–35%)
- +7% risk of low birth weight (95% CI: 1–12%)
- +10% risk of small-for-gestational-age infants (95% CI: 6–14%)
No threshold below which these associations disappear has been identified. Current guidelines recommend ≤200 mg/day during pregnancy.[31]
Psychological risks
Caffeine has dose-dependent anxiety-producing properties[6][7]:
- Low doses (50–150 mg): Mild alerting, possible mood lift
- Moderate-to-high doses (200–500 mg): Anxiety, irritability, restlessness
- High doses (>500 mg): Palpitations, marked anxiety, possible panic attacks
- Very high doses: Rare psychotic or manic symptoms have been reported[6]
Individuals with panic disorder are particularly vulnerable — caffeine challenge reliably triggers panic attacks in this population.[7] Genetic variation in the ADORA2A gene (encoding the A₂A receptor) further modulates the anxiogenic threshold.[6]
Caffeine withdrawal symptoms can closely mimic psychiatric disorders (anxiety, depression, cognitive impairment), representing a documented source of clinical misdiagnosis.[8]
Tolerance and dependence
Tolerance develops to many of caffeine's effects with regular use, particularly locomotor stimulation.[1] The mechanism involves upregulation of adenosine receptors and adaptation of receptor complexes in the striatum.[12] Tolerance to wakefulness-promoting effects is incomplete — caffeine remains wake-promoting even in chronic users, though the effect is blunted.[13]
Physical and psychological dependence are both low-to-moderate. Abuse potential is low — caffeine does not produce the reinforcement profile of classical drugs of abuse, though it acts as a weak reinforcer.[1] Caffeine Use Disorder is designated for further study in the DSM-5, while Caffeine Withdrawal is a fully diagnosable condition.[8]
Withdrawal syndrome (DSM-5 recognized)[8]:
- Onset: 12–24 hours after last dose
- Peak: 20–51 hours
- Duration: 2–9 days
- Symptoms: Headache (most common), fatigue, low mood, difficulty concentrating, irritability, flu-like symptoms
- Mechanism: Withdrawal headache results from rebound effect blood vessel dilation in the brain following cessation of caffeine's constricting effect[27]
Drug interactions
CYP1A2 metabolic interactions
Because a single liver enzyme (CYP1A2) handles ~95% of caffeine metabolism, any drug that strongly inhibits this enzyme dramatically increases caffeine exposure. Fluvoxamine is the most clinically significant: standard doses increase caffeine's half-life from approximately 5 hours to 31 hours.[32][33] Even low-dose fluvoxamine (10–20 mg/day) substantially inhibits caffeine metabolism.[34]
Patients starting fluvoxamine who maintain their usual caffeine intake risk caffeine toxicity. Other clinically relevant CYP1A2 inhibitors include ciprofloxacin, enoxacin, and oral contraceptives.[16]
Conversely, tobacco smoking accelerates caffeine clearance by 40–65%.[21][16] Smoking cessation therefore unmasks higher caffeine levels, potentially triggering toxicity symptoms in heavy coffee drinkers.
Stimulant combinations
Caffeine profoundly enhances MDMA toxicity in preclinical models: dramatically increasing hyperthermia, rapid heart rate, cardiovascular toxicity, mortality, and long-term serotonergic neurotoxicity.[35] Similar enhancement of toxicity applies to cocaine, amphetamine, and ephedrine combinations.[35]
Caffeine and alcohol
Caffeine partially masks the subjective feeling of alcohol intoxication but does not reduce blood alcohol levels or actual impairment.[36] Users of caffeine–alcohol combinations (particularly energy drink mixers) may dangerously overestimate their ability to drive or function safely.
Adenosine receptor drugs
Caffeine directly opposes the therapeutic effects of intravenous adenosine (used for heart rhythm emergencies) and adenosine-based cardiac stress test agents (regadenoson, dipyridamole). Caffeine must be avoided for 12–24 hours before heart perfusion imaging.
Contraindications
Panic disorder and anxiety disorders: Caffeine reliably provokes panic attacks in patients with panic disorder and worsens generalized anxiety.[7] Individuals with these conditions should minimize or avoid caffeine.
Heart rhythm disorders: High-dose caffeine directly triggers dangerous heart rhythms through cardiac calcium overload.[11][28] Patients with pre-existing rhythm disorders or long QT syndrome should limit intake.
Pregnancy: Dose-dependent risks for miscarriage, stillbirth, and low birth weight with no identified safe threshold below 200 mg/day.[30]
CYP1A2 inhibitor co-administration: Patients on fluvoxamine, ciprofloxacin, or other potent CYP1A2 inhibitors face dramatically elevated caffeine exposure and should reduce intake proportionally.[32]
Newborns and infants: Absent CYP1A2 expression at birth results in half-lives of 65–100 hours.[22] Caffeine use in neonates is therapeutic and medically supervised only.
High blood pressure: Caffeine acutely raises blood pressure via catecholamine release; individuals with uncontrolled high blood pressure should monitor intake.
Harm Reduction[edit]
Forms & Identification
Caffeine's ubiquity means most users encounter it in well-labeled commercial products — brewed coffee, tea, energy drinks, soft drinks, and over-the-counter tablets — where identity is not in question. The risk landscape shifts with bulk caffeine powder and capsules purchased online, where potency is extreme and dosing accuracy requires precision equipment.
Energy drinks pose a distinct challenge: caffeine content varies widely between brands and is not always prominently displayed. A single can may contain anywhere from 80 to 300+ mg. When multiple cans are consumed in sequence — particularly in combination with alcohol — total intake can reach toxic ranges without the consumer recognizing it.
Guidelines
- Know your dose: a standard cup of brewed coffee contains approximately 80–100 mg of caffeine; espresso ~63 mg per shot; energy drinks vary from 80 to 300+ mg per container
- Start lower if caffeine-naïve or returning after a break — 50–100 mg provides a meaningful effect without established tolerance
- Avoid caffeine within 6–8 hours of intended sleep time
- If you experience consistent anxiety from caffeine, consider reducing dose rather than pushing through — ADORA2A genetic variants make some individuals genuinely more vulnerable
- Never use bulk caffeine powder without a milligram-precision scale — a single teaspoon contains approximately 3,200 mg
- Advisory daily limits: ≤400 mg for adults, ≤200 mg during pregnancy
Set & Setting
Caffeine is rarely considered in set-and-setting terms, but context matters more than most users realize. The same 200 mg dose that produces focused productivity during a calm morning can generate restless anxiety when consumed under stress or time pressure. Genetic variation in adenosine receptors means some individuals are inherently more anxiety-prone in response to caffeine — those who notice anxiety as a consistent effect should treat it as biological signal, not personal weakness.
Sleep timing deserves particular attention. Caffeine's 3–5 hour half-life means a late-afternoon dose still has significant stimulant activity at bedtime. Chronic sleep disruption from caffeine creates a self-reinforcing cycle: poor sleep increases fatigue, which increases caffeine consumption, which further disrupts sleep.
Aftercare & integration. After acute overconsumption (>500 mg), prioritize hydration, electrolyte replacement, and sleep once the stimulant effects subside. The body recovers fastest when metabolic demands are reduced. Avoid additional stimulants for at least 24 hours.
For those reducing or quitting habitual caffeine use, withdrawal management is the primary aftercare concern. Taper gradually — reducing by 25% every few days — rather than stopping abruptly. Expect headache, fatigue, and low mood peaking at 20–51 hours after the last dose, resolving within 2–9 days. Over-the-counter pain suppression can manage withdrawal headache; adequate hydration and extra sleep support recovery.
Recovery & Support
Caffeine dependence is real but generally mild compared to other substance dependencies. The DSM-5 recognizes Caffeine Withdrawal as a diagnosable condition and designates Caffeine Use disorder for further study. Most people who wish to quit or reduce can do so independently through gradual tapering over 1–2 weeks.
For individuals who find caffeine use genuinely difficult to control — particularly those consuming >500 mg daily or experiencing significant anxiety, sleep disruption, or repeated failed quit attempts — structured support may help. Cognitive behavioral approaches used for other substance dependencies apply to caffeine. A healthcare provider can help rule out underlying conditions (anxiety disorders, sleep disorders) that may be driving excessive use.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable but safe: jitteriness, mild nausea, rapid heartbeat that resolves within an hour. Needs immediate help: chest pain, seizure, severe confusion, loss of consciousness, uncontrollable vomiting, or a heart rate that feels irregular rather than simply fast.
Immediate steps:
- 1. Call emergency services if the person has seized, lost consciousness, or reports chest pain
- 2. Do not induce vomiting
- 3. If conscious and ingestion was within the last 1–2 hours, emergency services may administer activated charcoal
- 4. Place an unconscious person in the recovery position
- 5. Monitor breathing and heart rate while waiting for help
What to tell the dispatcher: State the substance (caffeine), the estimated amount ingested, the time of ingestion, and current symptoms. Note whether the source was pills, powder, or energy drinks. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Caffeine is not a controlled or scheduled substance in any major jurisdiction. It is regulated as a food additive and pharmaceutical ingredient, with regulatory attention focused on concentration limits in consumer products rather than access restrictions. The FDA and EFSA have established recommended daily intake limits (400 mg for adults, 200 mg for pregnant women), but these are advisory rather than legally enforced.[31][29] The most significant regulatory action in recent years was the 2018 FDA guidance effectively banning direct-to-consumer sale of highly concentrated or pure powdered caffeine following overdose fatalities.[29]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not scheduled; GRAS food additive | GRAS at ≤200 ppm in cola-type beverages. OTC stimulant under FDA monograph. FDA recommends ≤400 mg/day. Bulk powdered caffeine effectively banned for consumer sale (2018)[29] |
| European Union | Not controlled | EFSA limits: ≤400 mg/day adults, ≤200 mg single dose, ≤200 mg/day pregnant women. No safe limit established for children/adolescents[31] |
| United Kingdom | Not controlled | Food Standards Agency aligns with EFSA limits (≤400 mg/day adults) |
| Canada | Not scheduled | Health Canada: ≤400 mg/day adults, ≤300 mg/day pregnant women |
| Australia | Not scheduled | TGA regulates caffeine-containing medicines; FSANZ sets food standards |
| International sport (WADA) | Monitoring Program | Removed from Prohibited List in 2004; remains on the Monitoring Program |
references
- [1]
- [2] ^abcFredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. — Pharmacological Reviews doi:10.1124/pr.110.003285
- [3]
- [4] ^abSchmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W (2006) Caffeine therapy for apnea of prematurity. — New England Journal of Medicine doi:10.1056/nejmoa054065
- [5] ^abcCunha RA, Agostinho PM (2010) Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. — Journal of Alzheimer's Disease doi:10.3233/jad-2010-1408
- [6]